Kornimate/medical-research-clean huggingface dataset:
scapular alignment and upper limb function in children with cerebral palsy

Conditions: Cerebral Palsy

Summary: purpose: to determine the effect of scapular alignment on upper limb function in hemiparetic children and to find relation between scapular alignment of the affected, less affected limb and the upper limb function in children with spastic hemiparesis subjects: forty children with spastic hemiparetic cerebral palsy, from both genders, were included in this study. they were selected from outpatient clinic of faculty of physical therapy, cairo university. the age of the selected children was ranging from 3 to 6 years old. degree of spasticity is ranging from 1 to 1+ according to modified ashworth scale. methods: forty children with spastic hemiparetic cerebral palsy were assessed for scapular alignment using postural zone software and for upper limb function using pediatric arm function test.

subjects: forty children with spastic hemiplegic cp, from both genders, were included in this study. they were selected from outpatient clinic of faculty of physical therapy, cairo university. inclusion criteria: children were enrolled in this study according to the following criteria: 1. the age of the selected children was ranging from 3 to 6 years old . 2. both genders were included. 3. they were able to follow instructions and understand commands. 4. degree of spasticity is ranging from 1 to 1+ according to modified ashworth scale. 5. postural zone software was assess scapular alignment and pediatric arm function test was assess upper arm function . exclusion criteria: the child was excluded from the study if he / she has one or more of the following: 1. upper limb surgery in the last 12 months. 2. children which had contracture, fracture, and fixed deformities in the upper limb. 3. children with muscleoskletal abnormalities as fixed back deformities. methods: forty children with spastic hemiparetic cerebral palsy were assessed for scapular alignment using postural zone software and for upper limb function using pediatric arm function test.

Eligibility criteria:
inclusion criteria: 1. the age of the selected children was ranging from 3 to 6 years old . 2. both genders were included. 3. they were able to follow instructions and understand commands. 4. degree of spasticity is ranging from 1 to 1+ according to modified ashworth scale. exclusion criteria: 1. upper limb surgery in the last 12 months. 2. children which had contracture, fracture, and fixed deformities in the upper limb. 3. children with muscleoskletal abnormalities as fixed back deformities.
reliability of posterior shoulder endurance test in overhead athletes

Conditions: Shoulder Pain; Healthy

Summary: the purpose of this study was to investigate the reliability of posterior shoulder endurance test in overhead athletes and to compare the endurance of posterior shoulder muscles between athletes with and without shoulder pain.

a total of 40 overhead athletes, 20 with shoulder pain and 20 with no shoulder pain, will be included in the study. shoulder endurance will be measured as isometric and isotonic on both arms of athletes using the posterior shoulder endurance test. the measurements will be repeated after 3-7 days, and the test-retest reliability of the isotonic and isometric posterior shoulder endurance test will be investigated.

Eligibility criteria:
inclusion criteria: for all athletes: * being between the ages of 13-24, * participating to overhead sports (tennis, volleyball, handball, etc.), * training at least 2-3 hours a week, * active participation in training and competitions, * to be able to complete all assessments in the study, for athletes with shoulder pain: * shoulder pain is 3/10 or more in the visual analogue scale. for athletes without shoulder pain: * no shoulder pain (0/10 according to visual analog scale) * no history of a shoulder injury and/or shoulder symptoms requiring treatment for the past 1 year. * having 90/100 or higher results in kerlan-jobe orthopedic clinical shoulder \& elbow score exclusion criteria: * bilateral shoulder pain, * upper extremity fracture history, * surgical history of shoulder, cervical and thoracic region, * diagnosis of musculoskeletal disease in the cervical region, elbow, and wrist, * neck and shoulder pain with active/passive cervical spine movement, * frozen shoulder, * multidirectional joint hypermobility, * having a systemic musculoskeletal disease, * diagnosis of chest deformity and scoliosis.
treatment of patients with human immunodeficiency virus (hiv)-related chronic diarrhea with saccharomyces boulardii or placebo: a double blind trial

Conditions: Diarrhea; HIV Infections

Summary: to assess the efficacy of saccharomyces boulardii (a nonpathogenic yeast) in producing a significant reduction in diarrheal symptoms in hiv-infected patients with chronic diarrhea.


Eligibility criteria:
inclusion criteria concurrent medication: allowed: * antiviral medication for hiv infection. patients must have: * documented hiv infection. * chronic diarrhea (for at least 1 month) that is either a manifestation or complication of documented hiv infection. * had a stool culture (salmonella, shigella, campylobacter, and clostridium difficile) and stool analysis for ova and parasite (o/p x 3) within the past 2 months. * failed antimicrobial treatment for diarrhea or received no prior antimicrobials for stool pathogens because stool cultures were negative. patients who are on antiviral medications for hiv infection must have received such medication for at least 2 weeks and must remain on stable dose for weeks 1 and 2 of study. prior medication: allowed: * prior antiviral medication for hiv infection (if on such medication, must have received it for at least 2 weeks). * standard antimicrobial therapy for a documented positive gastrointestinal pathogen. exclusion criteria concurrent medication: excluded: * gastrointestinal medications that cause diarrhea (e.g., magnesium-containing antacids, lactulose). * maintenance antifungal medication for life-threatening fungal infections (other than fluconazole \<= 100 mg/day).

Keywords: diarrhea acquired immunodeficiency syndrome aids-related complex saccharomyces
controlled co2 inhalation in noh

Conditions: Neurogenic Orthostatic Hypotension

Summary: this study focuses on neurogenic orthostatic hypotension (noh), which is a disorder characterized by an abnormal drop in blood pressure (bp) within 3-minutes of standing. patients with noh experience debilitating symptoms including light-headedness, falls, and fainting. patients often struggle with day-to-day tasks that require standing, with a reduced quality-of-life. current therapies for noh have limited effectiveness and unwanted side effects. our lab has found that raising blood co2 levels (hypercapnia) in the lab increases bp when standing in patients with noh. we now aim to test the carbohaler, an exogenous controlled co2 delivery device, in this study to see if increasing co2 levels through controlled co2 inhalation can improve bp and reduce symptoms in patients with noh when standing up. on the study day, participants will undergo two head-up tilt (hut; upright) tests with different breathing protocols: one with and one without exogenous co2 delivery provided by a co2 inhalational device. we will record heart rate, blood pressure, and breathing parameters. we will also assess upright symptoms using the vanderbilt orthostatic symptoms score. our primary outcome is the magnitude of the change in systolic bp from lying down to standing, which will be compared with and without exogenous co2 delivery. we hypothesize that exogenous co2 delivery provided by a co2 inhalational device will raise co2 enough to increase standing bp, which could reduce the debilitating symptoms experienced by patients with noh. we hope that these data will support future clinical trials, with the long-term goal of creating a simple, low-cost treatment for increasing quality-of-life for patients with noh.


Eligibility criteria:
inclusion criteria: * age ≥18 years * male and female * physician diagnosis of neurogenic orthostatic hypotension * non-smokers. * able and willing to provide informed consent. * ability to travel to libin cardiovascular institute autonomic testing lab at the university of calgary, calgary, ab. exclusion criteria: * pregnant or breast-feeding females * subjects with chronic heart failure or severe pulmonary disease who are unable to climb one flight of stairs due to shortness of breath. * presence of failure of other organ systems or systemic illness that can affect autonomic function or the participant's ability to cooperate. these include dementia, alcohol and/or drug abuse. * other factors which in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies.

Keywords: neurogenic orthostatic hypotension autonomic cardiovascular therapies quality-of-life symptom-management novel
relevance of peripheral cells in the pathophysiology of chronic myelomonocytic leukemia (cmml)

Conditions: Chronic Myelomonocytic Leukemia

Summary: chronic myelomonocytic leukemia (cmml) is the most frequent of myelodysplastic/myeloproliferative syndromes, as defined by the who classification of myeloid malignancies. the median age at diagnosis is around 70 years with a strong male predominance. cmml is a clonal disease of the bone marrow hematopoietic stem cell mainly characterized by persistent monocytosis (\>1x109/l) and the presence of immature dysplastic granulocytes in the peripheral blood of cmml patients. allogeneic stem cell transplantation (asct) remains the only curative option in cmml. however, cmml patients are rarely eligible for this kind of therapy, mainly due to their advanced age. the gold standard treatment of cmml thus remains hydroxyurea, which is usually initiated when the disease becomes proliferative, and demethylating agents, which could be efficient in the most aggressive forms of cmml. nevertheless, the pathogenesis of cmml remains poorly understood and new therapies are urgently needed for patients in treatment failure. in recent years, a large numbers of gene mutations have been discovered in cmml, none of which are specific of this entity, as they can be encountered with different frequencies in other myeloid neoplasms. these mutated genes encode signaling molecules (nras, kras, cbl, jak2, flt3 and several members of the notch pathway), epigenetic regulators (tet2, asxl1, ezh2, idh1, idh2,.) and splicing factors (sf3b1, srsf2, zrsf2). mutations in the transcription regulators runx1, npm1 and tp53 have also been reported in cmml. however, the role of these mutations in leukemogenesis is still unclear. cmml is also characterized by defects in monocyte to macrophage differentiation. these defects in monocyte differentiation can be attributed to the presence of immature dysplastic granulocytes that secrete high levels of alpha-defensins hnp1-3 that antagonize the purinergic receptor p2ry6 in cmml patients. these cd14-/cd15+/cd24+ immature granulocytes that belong to the same clone than the leukemic monocytes seem to have immunosuppressive properties ressembling those of the myeloid-derived suppressor cells (mdcs) described in solid tumours. whether these immature granulocytes contribute to autoimmune manifestations or immunoescape and progression of cmml is a conendrum and remains to be determined. in this context, the proposed project aims at identifying news insights into the pathophysiology of cmml through a better definition of the phenotype and function of monocytes and immature granulocytes that characterize this pathology.


Eligibility criteria:
inclusion criteria: * patients newly diagnosed or undergoing treatment in the clinical hematology department of the participating establishments exclusion criteria: * na
understanding of psychotic disorders in children with 22q11.2ds

Conditions: 22q11.2 Deletion Syndrome

Summary: the study premices22 will investigate the prodromal signals at the onset of psychotic disorders of children with 22q11.2 deletion syndrome

22q11.2ds is one of the most common microdeletion syndromes (1 / 2000-1 / 4000 births) and one of the most robust genetic risk factors for schizophrenia (1 to 2% of cases). reciprocally, approximately 30% of patients with 22q11.2ds will develop psychotic symptoms in adolescence or early adulthood. it is now well established that children and adults with 22q11.2ds have lower social skills than developing youth. these social dysfunctions could be partly underpinned by alterations in social cognitive processes, and could also be linked to the emergence of psychotic signs or even schizophrenia. however, to our knowledge, no study has investigated the existence of behavioral prodromal signs during the onset of psychotic signs in children with 22q11.2ds. in addition, the origin of social cognitive processes remains to this day little explored.

Eligibility criteria:
inclusion criteria: * diagnosis of 22q11.2 deletion syndrome or no developmental disease * aged from 4 to 13 years old * french language exclusion criteria: * diagnosis of intellectual deficiency according to dsm 5 criteria * drug prescribed for somatic condition that could influence cerebral functioning
improving heart failure outcomes rural

Conditions: Heart Failure

Summary: this study will test if standardized care helps patients feel better, if it can be implemented in rural hospitals, and find out which healthcare processes and outcomes are most important to heart failure patients.

the aims of this research are to: 1) conduct a quasi-experimental study of rural hospitals to test if guideline-based care (standardized patient education, making a post discharge appointment with the patient's provider and calling the patient at 48 hours to reinforce hf education) improves patient outcomes (better self-care, and lower readmissions at 7 and 30 days post discharge); 2) identify hospital (staffing, practice environment, costs) and provider (evidence-based practices) characteristics associated with better implementation of heart failure patient care processes; and 3) determine which healthcare processes and outcomes are most important to heart failure patients. a quasi-experimental study with mixed methods will be used. the sample consists of hf patients (n=40, 20 each hospital) and nurses who care for hf patients on study units (n=90, 45 each hospital) from 2 rural hospitals. survey data will be collected from patients (baseline, discharge, 48 hours and 7 days post discharge) and nurses (baseline, during patient education, on patient discharge). secondary data will be collected quarterly on nurse staffing and once for patient readmission within 30 days of discharge. structured patient interviews will be conducted with 10 hf patients in person to determine which health care processes and outcomes are most important to them. both patients and nurses will be engaged to inform study procedures and outcomes consistent with the tenants of patient-centered outcomes research.

Eligibility criteria:
inclusion criteria: * admitted to hospital with a diagnosis of heart failure * age \> 20 * cognitively intact * english speaking * plan for discharge to home, assisted living or intermediate care exclusion criteria: * patients with planned discharge to sub-acute or nursing home facilities * patients enrolled in another research study to test interventions to improve heart failure knowledge, self-management or reduce readmission to the hospital within 30 days post discharge * patients that are cognitively impaired * patients that are transferred to another unit in the hospital, and will be discharged from that unit * patients who undergo or have a planned surgical intervention during their hospital stay
major depressive disorder in the elderly

Conditions: Depressive Disorder, Major

Summary: this is a placebo-controlled study evaluating the effectiveness of medication in elderly subjects with major depressive disorder (mdd).


Eligibility criteria:
inclusion criteria: * primary diagnosis of major depressive disorder with dsm-iv criteria for their current episode for at least 8 weeks. exclusion criteria: * patient has current or past history of seizure disorder or brain injury. * patient has a diagnosis of anorexia or bulimia within the past 12 months. * patient has a past or current dms-iv diagnosis of schizophrenia or any other psychotic disorder(s). * patient has had a myocardial infarction within 1 year or a history of uncontrolled hypertension or unstable heart disease with 6 months.

Keywords: mdd bupropion depression
observational study in covid-19 patients treated with remdesivir

Conditions: Hospitalization

Summary: taking into account the high number of covid-19 patients managed in italian internal medicine, fadoi foundation (italian scientific society of internal medicine) promotes a national retrospective observational study in patients treated with remdesivir, analyzing the characteristics of patients and their clinical outcome during hospitalization, and thus providing real-life information potentially useful to integrate the evidence produced by studies conducted under experimental conditions and available in the literature.

this is a multicenter observational, retrospective study, which involves the participation of 35 nationally representative internal medicine units, for each center data on all patients suffering from sars-cov-2 and treated with remdesivir are expected to be recorded. each center will have the task of collecting the data of patients hospitalized consecutively proceeding backwards until march 2020. the study is a no-profit scientific project, promoted by the fadoi foundation, the scientific society of internal medicine.

Eligibility criteria:
inclusion criteria: * patients aged ≥ 18 years * diagnosed with radiologically documented sars-cov-2 pneumonia * treated with remdesivir (according to the criteria defined by aifa\*) * admitted to internal medicine from march 2020 to august 2021. exclusion criteria: * none

Keywords: covid-19 patients remdesivir
perioperative muscle relaxant and postoperative outcomes

Conditions: Postoperative Complications

Summary: muscle relaxant is usually needed for surgery. however, the optimal depth of neuro-muscular blockade is still on debate. deep neuro-muscular blockade may benefit the patients during surgery, but may increase the risk of residual blockade after surgery. residual blockade has been reported to increase risk of morbidity. in this study, we tend to observe the postoperative outcomes in patients undergoing abdominal surgery under general anesthesia. and to compare the outcomes in patients received different depth of neuro-muscular blockade.


Eligibility criteria:
inclusion criteria: * age ≥18 years old * body mass \<18 kg/m2 * american society of anesthesiologists status i-ii * patients scheduled for elective laparoscopic colorectal or urological surgery * patients received general anesthesia and muscle relaxant * patients with written informed consent. exclusion criteria: * second surgery during the same admission. * outpatient surgery * retroperitoneal laparoscopic surgery * patients scheduled for mechanical ventilation after surgery * patients scheduled for muscle relaxant other than rocuronium * patients with pregnancy or planned for breeding * patients who are involved in other studies

Keywords: muscle relaxant general anesthesia chinese patient
level of physical activities in patients before and after breast cancer treatment

Conditions: Breast Cancer

Summary: subjects and methods: 303 patients who had already had the diagnosis of breast cancer and had already been treated at the ambulatory of botucatu school of medicine were selected. the measuring tool used for the level of physical activities was the international physical activities questionnaire (ipaq-short version), validated by the world health organization - physical activities and health international committee (1998).

introduction: breast cancer is the most common malignant neoplasy in women. the risk for breast cancer in a lifetime is high among north-american women, about one out of eight, with 66% of the cases occurring after menopause and 15% when women are under 40 years old. published cohort studies show clear evidences that women who practice intense physical activities have the risk for breast cancer reduced. the risk reduction for these women is 70%, and 10% for those who practice physical activities at a low level. during adolescence and adult age, moderate to intense physical activities may protect against a future breast cancer development. but some questions still need to be answered: were women with a breast carcinoma diagnosis already physically active during life? were there changes in these physical activities after treatment? why? objectives: the aim of this study was to identify the level of physical activities in patients before and after breast carcinoma treatment, and to observe if there were changes in the level of these activities. subjects and methods: 303 patients who had already had the diagnosis of breast cancer and had already been treated at the ambulatory of botucatu school of medicine were selected. the measuring tool used for the level of physical activities was the international physical activities questionnaire (ipaq-short version), validated by the world health organization - physical activities and health international committee (1998).

Eligibility criteria:
inclusion criteria: * patients whit diagnosis of breast cancer

Keywords: physical activity breast cancer
tenofovir disoproxil fumarate (tdf) in hiv-1 patients who have never taken anti-hiv drugs

Conditions: HIV Infections

Summary: the purpose of this study is to look at the effectiveness of tenofovir disoproxil fumarate (tdf) in hiv-infected patients who have never taken anti-hiv drugs.

patients receive tdf.

Eligibility criteria:
inclusion criteria patients may be eligible for this study if they: * are hiv-positive. * have a plasma viral load (level of hiv in the blood) of 10,000 copies/ml or more. * have a cd4 count of 50 cells/mm3 or more. * have a negative pregnancy test. * agree to use 2 forms of barrier birth control while on the study and for 30 days afterwards. * are 18 to 65 years old. exclusion criteria patients will not be eligible for this study if they: * have had treatment with any of the following types of anti-hiv drugs: nucleoside reverse transcriptase inhibitors, nucleotide reverse transcriptase inhibitors (e.g., adefovir dipivoxil or tdf), protease inhibitors, or nonnucleoside reverse transcriptase inhibitors. * have received a vaccination within 30 days before study entry. * have had a new aids-defining illness diagnosed within 30 days before study entry. * are taking any of the following: drugs that may cause kidney problems, including aminoglycoside antibiotics, cidofovir, cisplatin, foscarnet, intravenous (iv) amphotericin b, iv vancomycin, oral and iv ganciclovir, and valganciclovir; probenecid; chemotherapy; steroid drugs; interleukin-2; or investigational drugs. * are pregnant or breast-feeding. * have difficulty taking, absorbing, or tolerating drugs by mouth, as may be shown by long-term nausea or vomiting. * abuse alcohol or drugs. * have cancer other than kaposi's sarcoma or basal cell carcinoma. * have other infections that need injectable antibiotics within 15 days before study entry. * have had kidney or bone disease. * have any medical conditions or past treatments that the study investigator believes would make the patient unsuitable for the study.

Keywords: hiv-1 adenine anti-hiv agents viral load organophosphorus compounds